Understanding Your Diagnosis: AKT2-Related FPLD

Familial Partial Lipodystrophy (FPLD) is a group of rare, inherited conditions where the body cannot store fat normally. Instead of being distributed evenly under the skin, fat is often missing from the limbs and hips (lipoatrophy) and may accumulate in other areas, such as the face, neck, or internal organs ^[1][2].

While most cases of FPLD are caused by pathogenic variants in common genes like LMNA (FPLD2) or PPARG (FPLD3), your diagnosis involves the AKT2 gene ^[3][4]. This gene provides instructions for a protein that acts like a “master switch” for insulin signaling. When insulin binds to a cell, AKT2 tells that cell to take up sugar from the blood or to store fat ^[5][6]. Because AKT2 is so central to how your body processes energy, even a tiny change in this gene can drastically alter your metabolism.

The Extreme Rarity of AKT2 Variants

An AKT2 diagnosis is exceptionally rare. To give you a sense of scale, common forms of FPLD like FPLD2 are found in roughly 1 in 100,000 people in some regions ^[4]. In contrast, AKT2 variants are so uncommon that they are often only documented in individual case reports or single families worldwide ^[7][8].

Because of this rarity, medical literature is still evolving. You may see AKT2 referred to as FPLD5 in older reports, but modern clinical guidelines more frequently use FPLD5 to describe a different gene called CIDEC ^[9][3]. For this reason, your doctors will likely focus on your specific genetic variant (the exact “spelling error” in your DNA) rather than a numbered subtype.

It is also crucial to understand that simply finding a change in the AKT2 gene does not automatically mean you have the disease. A Variant of Uncertain Significance (VUS) means the laboratory found a change, but there is not enough evidence to know if it affects your health. A VUS should not be used to direct treatment or test family members. Only a pathogenic or likely pathogenic variant, interpreted by a medical geneticist, supports a diagnosis.

Why Your Specific Variant Matters

In AKT2-related disease, the “direction” of the mutation determines the symptoms. Not all AKT2 changes cause the same condition.

• Loss-of-Function Variants (e.g., p.Arg208Lys): These variants turn the “switch” off or make it less effective. This leads to severe insulin resistance, where the body makes insulin but cannot use it properly to move sugar into cells ^[8]. This can cause early-onset diabetes, high triglycerides, and liver fat (steatosis) ^[10][2].
• Gain-of-Function Variants (e.g., p.Glu17Lys): These variants turn the “switch” permanently on. This causes the body to act as if insulin is always present, even when it isn’t. The result is hypoketotic hypoglycemia—dangerously low blood sugar levels occurring without the usual backup energy sources (ketones) being produced ^[11][12]. This variant does not typically cause the fat loss seen in FPLD but can cause overgrowth of certain body parts ^[11][13].

Understanding Clinical Heterogeneity

AKT2-related conditions are characterized by clinical heterogeneity, meaning that two people with different variants—or even the same variant—can have very different experiences.

For example, while some variants cause classic FPLD with fat loss in the arms and legs, others cause localized fat abnormalities. One reported case of the p.Arg208Lys variant involved unusual fat accumulation in a specific area (the labia majora) rather than the widespread metabolic issues seen in other families ^[7]. Because your variant is so specific, your care team will use your genetic report to predict whether you are at higher risk for diabetes or hypoglycemia.

Management and Monitoring

Because AKT2 sits at the heart of the insulin pathway, management focuses on protecting your metabolic health. Standard care usually includes:

1. Metabolic Screening: Regular checks of HbA1c (average blood sugar), fasting insulin, and triglycerides (blood fats) ^[14][15].
2. Liver Health: Monitoring for hepatic steatosis (fatty liver) using imaging like ultrasound or MRI, as fat that cannot be stored under the skin often ends up in the liver ^[2][16].
3. Specialized Therapy: If you have severe metabolic complications and low levels of leptin (a hormone made by fat), your doctor may discuss treatments like metreleptin, which helps “tell” the brain how much fat is actually stored ^[17][18].
4. Glucose Support: For those with gain-of-function variants causing low blood sugar, management often involves frequent meals and complex carbohydrates like uncooked cornstarch to maintain stable energy ^[12][13].

Summary of AKT2 Phenotypes: